Treat, Reassess, Repair Authors: Jonathan W Cramer Published: 2026 ABSTRACT Corresponding AuthorKey Words: atrial septal defect, congenital heart defect, pulmonary hypertension, right ventricle Pulmonary arterial hypertension (PAH) associated with congenital heart disease remains among the most challenging clinical scenarios encountered in cardiovascular medicine. Despite the simple anatomic nature of atrial septal defects (ASDs), the coexistence of an ASD with severe pulmonary vascular disease creates a particularly challenging diagnostic and therapeutic scenario not uncommon to adult congenital heart disease (ACHD) teams. The case from Haile et al1 illustrates how advances in pulmonary vasodilator therapy, coupled with close longitudinal follow-up and multidisciplinary decision-making, are reshaping our thought process. For quite some time, severe pulmonary vascular disease has been considered a contraindication to ASD closure because elimination of the interatrial shunt could precipitate acute right ventricular failure by removing an important pressure-relieving "pop-off" mechanism. Consequently, patients with markedly elevated pulmonary vascular resistance were often considered permanently inoperable. However, increasing evidence suggests that operability for patients with ASDs and PAH should be viewed as a dynamic, rather than static, state. Contemporary PAH therapies—including phosphodiesterase-5 inhibitors, endothelin receptor antagonists, and prostacyclin pathway agents—can substantially reduce pulmonary vascular resistance in carefully selected patients. The 2022 European Society of Cardiology/European Respiratory Society Guidelines recognize that ASD closure may be considered after targeted PAH therapy in selected patients whose pulmonary vascular resistance improves to acceptable levels following comprehensive evaluation at experienced centers.2 Thus, rather than relying on a single hemodynamic measurement, serial assessment of pulmonary vascular resistance, shunt magnitude, right ventricular function, exercise capacity, and clinical status should guide individualized decision-making. This case exemplifies that philosophy. Sequential escalation to triple pulmonary vasodilator therapy resulted in progressive improvement in pulmonary vascular resistance over several years, ultimately permitting reconsideration of ASD closure. Further, the authors elected to graduate ASD closure while medically treating, by implanting a fenestrated occluder rather than pursue complete defect closure. This nuanced strategy preserved a controlled atrial communication while reducing excessive left-to-right shunting, thereby balancing right ventricular protection against the adverse effects of persistent volume overload. Such individualized procedural planning highlights the value of experienced ACHD and pulmonary hypertension programs capable of integrating complex hemodynamic data into patient-specific treatment strategies to achieve optimal outcomes for patients once thought inoperable. But it should not also be lost that this report also reinforces the biological heterogeneity of ASD-associated PAH. Unlike post-tricuspid shunts, secundum ASDs expose the pulmonary circulation primarily to chronic volume overload and only a minority of patients develop severe pulmonary vascular remodeling. This observation, the “2-hit hypothesis,” suggests that additional genetic, molecular, or environmental factors contribute to disease susceptibility and emphasizes that management should extend beyond anatomic considerations alone. Careful phenotyping remains essential when determining whether pulmonary hypertension is attributable to congenital heart disease, coincidental idiopathic PAH, or overlapping pathophysiologic mechanisms. Importantly, this case report is consistent with the growing body of literature supporting the treat-and-repair strategy. Registry data from the North American ASD-PAH Registry have demonstrated that a subset of patients initially considered ineligible for closure can undergo successful delayed intervention following pulmonary vasodilator therapy, with improvements in functional status, right ventricular remodeling, and survival.3 Additional single-center studies have similarly reported favorable outcomes following combination PAH therapy and subsequent fenestrated ASD closure in carefully selected patients.4 Although prospective randomized studies remain lacking, these observations collectively support a shift away from rigid operability criteria toward individualized reassessment after optimized medical therapy under the care of an ACHD and PAH specialist or team. Ultimately, this case is a wonderful example of how successful management of PAH–congenital heart disease extends beyond selecting the appropriate medication or intervention. It reflects the value of sustained multidisciplinary collaboration, serial invasive and noninvasive hemodynamic assessment, and patient-centered longitudinal care. As pulmonary hypertension therapies continue to evolve, so too must our approach to congenital shunt lesions once considered beyond repair. The authors are to be commended for documenting an exceptional long-term outcome that reinforces an important contemporary principle: in selected patients with ASD-associated PAH, operability is not fixed at diagnosis but may emerge through thoughtful medical optimization, careful reassessment, and individualized intervention. Cases such as this continue to refine our understanding of treat-and-repair strategies and provide valuable guidance for clinicians managing one of the most complex populations in cardiovascular medicine. Funding Support and Author Disclosures Dr Cramer has been a consultant for Medtronic (Minneapolis, Minnesota). Footnotes The author attests they are in compliance with human studies committees and animal welfare regulations of the author’s institution and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. References